Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANUSCO trial of parenteral nutrition plus chemotherapy versus best supportive nutritional care in previously treated pancreatic adenocarcinoma
ISRCTN60516908Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Apr 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid, SmofKabiven Peripheral, eicosapentaenoic acid + docosahexaenoic acid and 3 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg University. Primary endpoint: Event-free survival. Started Apr 2009; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acidSmofKabiven Peripheraleicosapentaenoic acid + docosahexaenoic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN60516908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60516908.